Immunomodulatory drugs could be part of a functional cure for Human Immunodeficiency Virus (HIV), but immunotherapies have so far proven ineffective. This is in part due to an incomplete understanding of the systems level host immune responses to immunotherapy. Non-human primate (NHP) data have shown that N-803, an interleukin-15 (IL-15) superagonist, can transiently reduce viral loads, but that efficacy wanes over time as more doses are given. This talk will describe our use of mathematical models of N-803 treatment in SIV-infected NHPs to estimate the contributions of three key mechanisms to treatment outcomes: 1) drug tolerance, 2) immune regulation and 3) viral escape. These models are then applied to inform treatment regimen design, advancing the potential impact of immunotherapy in HIV.

This talk is jointly run by the departments of Quantitative & Comp. Biology, UMontreal/CMM-Fields.

================================

The Zoom link and connection details are:

Zoom link: https://umontreal.zoom.us/j/94053083646?pwd=RE5aUTdXc3hEbHoyZUFEYksxZ000...

Meeting ID: 940 5308 3646

Passcode: 952444